Today @AltoNeuro began trading on the @NYSE under the ticker $ANRO. I founded Alto out of the desire to give patients better treatment options than those that are currently available. Today we take one step closer to our goal of making #PrecisionPsychiatry a reality.

RT @OgundipeOre: Amit is right. There’s evidence that behavioral experiments paired with EEGs allow us explain neural mechanisms in psychi…

RT @AltoNeuro: We’re looking forward to our Investor R&D day focused on the upcoming ALTO-100 Phase 2b data readout in #MajorDepressiveDiso…

RT @laurel_joy_gd: Yes yes yes! We have thrown a lot of effort into optimizing EEG for these kinds of individual differences goals in @pine…

RT @therealRYC: Awesome perspective piece by @AmitEtkin on what we need to bring biomarkers into clinical practice in Psychiatry. "...to…

RT @davidcarreon: Great discussion biomarkers. So glad that this is an actual conversation that's happening! Maybe one day we can routinely…

RT @JimCav: @AmitEtkin @JAMAPsych Finally. A major outlet breaks from fMRI fever and looks around at what else is out there. Hey guess…

RT @JTRobinsonLab: More quantitative biomarkers in psych is going to benefit everyone. Patients will get the right therapies faster and wil…

Critical to any such effort is simply collecting enough data to define signals and prospectively replicate them. It's time to re-examine current priorities to focus on true clinical translation, for which we argue that EEG is the missing piece with respect to neuroimaging.

RT @CaitlinBaltzer: Neuroimaging for de-risking drug development and…improving.clinical.outcomes. Incredible and necessary paper. @AmitEtk…

RT @AltoNeuro: 🎧 Our CEO @AmitEtkin discusses the intersection of neurotechnology & #psychiatry to approach treatments for #MentalHealth di…